Effects of glucagon-like peptide-1 receptor agonists and dual glucagon-like peptide-1 receptor agonists/glucose-dependent insulinotropic polypeptide on liver stiffness and steatosis evaluated through Fibroscan^®: a systematic review and meta-analysis.

IF 4.1 3区医学 Q1 MEDICINE, GENERAL & INTERNAL

Internal and Emergency Medicine Pub Date : 2026-09-01 Epub Date: 2026-05-15 DOI:10.1007/s11739-026-04384-0

Antonella Berardicurti, Settimio D'Andrea, Francesco Cipollone, Onorina Berardicurti, Cosima Schiavone, Andrea Boccatonda

{"title":"Effects of glucagon-like peptide-1 receptor agonists and dual glucagon-like peptide-1 receptor agonists/glucose-dependent insulinotropic polypeptide on liver stiffness and steatosis evaluated through Fibroscan®: a systematic review and meta-analysis.","authors":"Antonella Berardicurti, Settimio D'Andrea, Francesco Cipollone, Onorina Berardicurti, Cosima Schiavone, Andrea Boccatonda","doi":"10.1007/s11739-026-04384-0","DOIUrl":null,"url":null,"abstract":"Metabolically associated fatty liver disease (MASLD) is highly prevalent among individuals with obesity and type 2 diabetes. Glucagon-like peptide-1 receptor agonists (GLP1-RA) and glucagon-like peptide-1 receptor agonists/glucose-dependent insulinotropic polypeptide (GLP1-RA/GIP) dual agonists have demonstrated favorable effects on liver health. Liver steatosis and stiffness can be noninvasively assessed using transient elastography with Fibroscan®. However, evidence regarding the impact of incretin therapy on these elastographic outcomes remains inconsistent across available studies. Indeed, we performed a systematic review and meta-analysis of randomized-controlled trials and case-control studies, which aimed to investigate the effect of GLP1-RA or GLP1-RA/GIP on liver stiffness and steatosis evaluated with Fibroscan® (PROSPERO registration number CRD420251162316). We searched PubMed, Web of Science, and Scopus for English-language studies till March 2025. Methodological quality of the studies was assessed by the Newcastle-Ottawa Scale or Jadad score. In the presence of heterogeneity, standardized (Std) mean differences with 95% confidence intervals (CIs) were combined using a random effect model. Funnel plot and trim-and-fill analysis were used to assess publication bias. Five studies were included in the analysis, accounting for 9 trials. A total of 554 patients and 270 controls were enrolled. The analysis revealed an improvement for both liver stiffness [std. mean difference = - 0.3, 95%CI - 0.5 to - 0.1, p = 0.02] and liver steatosis [std. mean difference = - 0.4, 95%CI - 0.7 to - 0.1, p = 0.03] at the end of the trial. Our findings showed that treatment with GLP1-RA and GLP1-RA/GIP in people with MASLD improves liver stiffness and steatosis evaluated through Fibroscan®.","PeriodicalId":13662,"journal":{"name":"Internal and Emergency Medicine","volume":" ","pages":"1979-1990"},"PeriodicalIF":4.1000,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Internal and Emergency Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11739-026-04384-0","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/5/15 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

Abstract

Metabolically associated fatty liver disease (MASLD) is highly prevalent among individuals with obesity and type 2 diabetes. Glucagon-like peptide-1 receptor agonists (GLP1-RA) and glucagon-like peptide-1 receptor agonists/glucose-dependent insulinotropic polypeptide (GLP1-RA/GIP) dual agonists have demonstrated favorable effects on liver health. Liver steatosis and stiffness can be noninvasively assessed using transient elastography with Fibroscan^®. However, evidence regarding the impact of incretin therapy on these elastographic outcomes remains inconsistent across available studies. Indeed, we performed a systematic review and meta-analysis of randomized-controlled trials and case-control studies, which aimed to investigate the effect of GLP1-RA or GLP1-RA/GIP on liver stiffness and steatosis evaluated with Fibroscan^® (PROSPERO registration number CRD420251162316). We searched PubMed, Web of Science, and Scopus for English-language studies till March 2025. Methodological quality of the studies was assessed by the Newcastle-Ottawa Scale or Jadad score. In the presence of heterogeneity, standardized (Std) mean differences with 95% confidence intervals (CIs) were combined using a random effect model. Funnel plot and trim-and-fill analysis were used to assess publication bias. Five studies were included in the analysis, accounting for 9 trials. A total of 554 patients and 270 controls were enrolled. The analysis revealed an improvement for both liver stiffness [std. mean difference = - 0.3, 95%CI - 0.5 to - 0.1, p = 0.02] and liver steatosis [std. mean difference = - 0.4, 95%CI - 0.7 to - 0.1, p = 0.03] at the end of the trial. Our findings showed that treatment with GLP1-RA and GLP1-RA/GIP in people with MASLD improves liver stiffness and steatosis evaluated through Fibroscan^®.

查看原文本刊更多论文

通过Fibroscan®评估胰高血糖素样肽-1受体激动剂和双胰高血糖素样肽-1受体激动剂/葡萄糖依赖性胰岛素多肽对肝脏僵硬和脂肪变性的影响：一项系统综述和荟萃分析

代谢性脂肪性肝病（MASLD）在肥胖和2型糖尿病患者中非常普遍。胰高血糖素样肽-1受体激动剂（GLP1-RA）和胰高血糖素样肽-1受体激动剂/葡萄糖依赖性胰岛素多肽（GLP1-RA/GIP）双激动剂已被证明对肝脏健康有良好的影响。肝脏脂肪变性和硬度可以使用纤维扫描®瞬时弹性成像无创评估。然而，关于肠促胰岛素治疗对这些弹性结果的影响的证据在现有的研究中仍然不一致。事实上，我们对随机对照试验和病例对照研究进行了系统回顾和荟萃分析，旨在研究GLP1-RA或GLP1-RA/GIP对肝脏僵硬和脂肪变性的影响，该影响由Fibroscan®（PROSPERO注册号CRD420251162316）评估。我们检索了PubMed， Web of Science和Scopus的英语研究，直到2025年3月。研究的方法学质量通过纽卡斯尔-渥太华量表或Jadad评分进行评估。在异质性存在的情况下，使用随机效应模型将标准化（Std）平均差异与95%置信区间（ci）结合起来。采用漏斗图和修剪填充分析评估发表偏倚。本分析纳入5项研究，共9项试验。共有554名患者和270名对照组被纳入研究。分析显示，在试验结束时，肝脏硬度[std. mean difference = - 0.3, 95%CI - 0.5至- 0.1,p = 0.02]和肝脏脂肪变性[std. mean difference = - 0.4, 95%CI - 0.7至- 0.1,p = 0.03]均有改善。我们的研究结果显示，GLP1-RA和GLP1-RA/GIP治疗MASLD患者可改善肝脏僵硬和脂肪变性，通过Fibroscan®评估。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Internal and Emergency Medicine 医学-医学：内科

CiteScore

7.20

自引率

4.30%

发文量

258

审稿时长

6-12 weeks

期刊介绍： Internal and Emergency Medicine (IEM) is an independent, international, English-language, peer-reviewed journal designed for internists and emergency physicians. IEM publishes a variety of manuscript types including Original investigations, Review articles, Letters to the Editor, Editorials and Commentaries. Occasionally IEM accepts unsolicited Reviews, Commentaries or Editorials. The journal is divided into three sections, i.e., Internal Medicine, Emergency Medicine and Clinical Evidence and Health Technology Assessment, with three separate editorial boards. In the Internal Medicine section, invited Case records and Physical examinations, devoted to underlining the role of a clinical approach in selected clinical cases, are also published. The Emergency Medicine section will include a Morbidity and Mortality Report and an Airway Forum concerning the management of difficult airway problems. As far as Critical Care is becoming an integral part of Emergency Medicine, a new sub-section will report the literature that concerns the interface not only for the care of the critical patient in the Emergency Department, but also in the Intensive Care Unit. Finally, in the Clinical Evidence and Health Technology Assessment section brief discussions of topics of evidence-based medicine (Cochrane’s corner) and Research updates are published. IEM encourages letters of rebuttal and criticism of published articles. Topics of interest include all subjects that relate to the science and practice of Internal and Emergency Medicine.